Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00280839 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of Topiramate to Aid in Smoking Cessation
A Phase 3 study of Smoking Cessation, sponsored by Lindner Center of HOPE.
- Completed
- Registry status
- Phase 3
- Development phase
- 87
- Enrollment target
- 1
- Study location
NCT00280839 is a Phase 3 study of Smoking Cessation that has completed, run by Lindner Center of HOPE. The registered enrollment target is 87 participants, below the 474-participant average among 188 other Smoking Cessation trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00280839, a Phase 3 study of Smoking Cessation, has completed, sponsored by Lindner Center of HOPE.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 87 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to determine if topiramate is safe and effective in the treatment of smoking cessation
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Topiramate
Study Locations (1)
Ohio
- University of Cincinnati Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00280839
The ClinicalTrials.gov registry entry for NCT00280839 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 474-participant average among 188 other Smoking Cessation trials with a reported enrollment target (82% lower). The listed sponsor is Lindner Center of HOPE, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Smoking Cessation appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00280839 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT00280839 about?
NCT00280839 is a clinical study titled "Safety and Efficacy Study of Topiramate to Aid in Smoking Cessation". The purpose of this research study is to determine if topiramate is safe and effective in the treatment of smoking cessation
What is the current status of trial NCT00280839?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 87 participants.
What conditions does trial NCT00280839 study?
This clinical trial studies the following conditions: Smoking Cessation.
What interventions are being tested in trial NCT00280839?
The interventions under investigation include: Placebo (DRUG), Topiramate (DRUG).
Who is sponsoring clinical trial NCT00280839?
This trial is sponsored by Lindner Center of HOPE, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00280839 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking Cessation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tobacco Education and Lung Health Study (TEAL)
RECRUITING · Phase 3
-
V+PSF-M for Tobacco Cessation in HIV Care in India
RECRUITING · Phase 3
-
Improving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment
RECRUITING · Phase 3
-
Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype
COMPLETED · Phase 3
-
Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD).
COMPLETED · Phase 3
-
Nicotine Mouth Film for Craving Relief.
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.